Regulus Therapeutics Inc. (NASDAQ:RGLS)’s share price traded up 2.5% during mid-day trading on Friday . The company traded as high as $3.27 and last traded at $3.24, with a volume of 291,182 shares trading hands. The stock had previously closed at $3.16.

A number of equities analysts have recently issued reports on the stock. Needham & Company LLC reiterated a “buy” rating on shares of Regulus Therapeutics in a report on Tuesday, May 3rd. Cowen and Company reiterated a “buy” rating on shares of Regulus Therapeutics in a report on Monday, May 2nd. BMO Capital Markets reissued a “buy” rating on shares of Regulus Therapeutics in a research note on Monday, May 2nd. Wells Fargo & Co. initiated coverage on shares of Regulus Therapeutics in a research note on Tuesday, May 3rd. They issued a “buy” rating on the stock. Finally, Zacks Investment Research raised shares of Regulus Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, June 29th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $10.17.

The stock has a 50 day moving average of $3.51 and a 200-day moving average of $5.46. The stock’s market cap is $171.14 million.

Regulus Therapeutics (NASDAQ:RGLS) last announced its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by $0.02. Equities analysts predict that Regulus Therapeutics Inc. will post ($1.59) earnings per share for the current fiscal year.

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.